JP2024533378A - ワクチン産生のための生物学的に産生された核酸 - Google Patents

ワクチン産生のための生物学的に産生された核酸 Download PDF

Info

Publication number
JP2024533378A
JP2024533378A JP2024515395A JP2024515395A JP2024533378A JP 2024533378 A JP2024533378 A JP 2024533378A JP 2024515395 A JP2024515395 A JP 2024515395A JP 2024515395 A JP2024515395 A JP 2024515395A JP 2024533378 A JP2024533378 A JP 2024533378A
Authority
JP
Japan
Prior art keywords
acid sequence
amino acid
cov
sars
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024515395A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024533378A5 (https=
JPWO2023036947A5 (https=
Inventor
タチアーナ キッパー，エンヤ
クリムカイト，トーマス
ミッテルホルツァー，クリスチャン
オッティ，ファビアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Basel
Original Assignee
Universitaet Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Basel filed Critical Universitaet Basel
Publication of JP2024533378A publication Critical patent/JP2024533378A/ja
Publication of JP2024533378A5 publication Critical patent/JP2024533378A5/ja
Publication of JPWO2023036947A5 publication Critical patent/JPWO2023036947A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • C12N2770/20052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024515395A 2021-09-09 2022-09-09 ワクチン産生のための生物学的に産生された核酸 Pending JP2024533378A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21195643 2021-09-09
EP21195643.8 2021-09-09
EP22179777 2022-06-19
EP22179777.2 2022-06-19
PCT/EP2022/075140 WO2023036947A1 (en) 2021-09-09 2022-09-09 Biologically produced nucleic acid for vaccine production

Publications (3)

Publication Number Publication Date
JP2024533378A true JP2024533378A (ja) 2024-09-12
JP2024533378A5 JP2024533378A5 (https=) 2025-09-18
JPWO2023036947A5 JPWO2023036947A5 (https=) 2025-09-18

Family

ID=83558295

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024515395A Pending JP2024533378A (ja) 2021-09-09 2022-09-09 ワクチン産生のための生物学的に産生された核酸

Country Status (9)

Country Link
US (1) US20250188127A1 (https=)
EP (1) EP4398935A1 (https=)
JP (1) JP2024533378A (https=)
KR (1) KR20240055051A (https=)
AU (1) AU2022341555A1 (https=)
CA (1) CA3224963A1 (https=)
IL (1) IL310010A (https=)
MX (1) MX2024002259A (https=)
WO (1) WO2023036947A1 (https=)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022543046A (ja) * 2019-07-30 2022-10-07 バーンダリ・インコーポレイテッド ウイルス様粒子ワクチン

Also Published As

Publication number Publication date
KR20240055051A (ko) 2024-04-26
AU2022341555A1 (en) 2024-01-18
WO2023036947A1 (en) 2023-03-16
IL310010A (en) 2024-03-01
EP4398935A1 (en) 2024-07-17
MX2024002259A (es) 2024-03-06
AU2022341555A9 (en) 2024-01-25
CA3224963A1 (en) 2023-03-16
US20250188127A1 (en) 2025-06-12

Similar Documents

Publication Publication Date Title
Andersson et al. A defined subgenomic fragment of in vitro synthesized Moloney sarcoma virus DNA can induce cell transformation upon transfection
Bálint et al. Molecular characterization of feline infectious peritonitis virus strain DF-2 and studies of the role of ORF3abc in viral cell tropism
Youn et al. In vitro assembled, recombinant infectious bronchitis viruses demonstrate that the 5a open reading frame is not essential for replication
CN107267532B (zh) PEDV JS2008株全长感染性cDNA的构建方法及应用
CN110079541A (zh) 一种构建冠状病毒感染性克隆的方法及其应用
CN101948811B (zh) 用反向遗传操作拓展口蹄疫疫苗株抗原谱及疫苗制备方法
EP1736539A1 (en) Attenuated SARS-CoV vaccines
EP3158060B1 (en) Method for rapid generation of an infectious rna virus
KR20040032791A (ko) 일본뇌염 바이러스의 신규한 전체-길이의 게놈 ＲＮＡ 및상기 ＪＥＶ 게놈 ＲＮＡ에 대한 감염성이 있는 ＪＥＶｃＤＮＡ 및 이것의 용도
CN106755089A (zh) 表达山羊淋巴细胞活化分子的细胞系及其构建方法与应用
CN110904055B (zh) 猪繁殖与呼吸综合征病毒重组疫苗株prrsv-sp及其制备方法与应用
Li et al. Rapid reconstruction of infectious bronchitis virus expressing fluorescent protein from its nsp2 gene based on transformation-associated recombination platform
CN113736799A (zh) 山羊副流感病毒3型感染性cDNA克隆构建方法及其应用
JP2024533378A (ja) ワクチン産生のための生物学的に産生された核酸
US20080131459A1 (en) Full-Length Infectious Cdna Clone for Porcine Reproductive and Respiratory Syndrome Virus(Prrsv) and Uses Thereof
AU736586B2 (en) An infectious clone for human parainfluenza virus type 3
CN118076383A (zh) 用于疫苗生产的生物学方法产生的核酸
Yun et al. Bacterial artificial chromosomes: A functional genomics tool for the study of positive-strand RNA viruses
CN118620850B (zh) 一种禽传染性支气管炎病毒弱毒株的制备及其应用
US20230203536A1 (en) Coronavirus rna replicons and use thereof as vaccines
Sugiura et al. Expression of spike and hemagglutinin-esterase proteins is necessary to recover infectious recombinant bovine coronavirus
CN111235114A (zh) 一种ev71复制缺陷型病毒及其制备方法和应用
CN116004551B (zh) 一种调节mhc-ii类反式激活因子ciita基因的猪繁殖与呼吸综合征病毒活疫苗的构建及其应用
CN117736276A (zh) 肠道病毒71型vp1蛋白高保守位点突变致流产株感染性克隆及其构建方法和应用
Eriksson et al. Efficient transduction of dendritic cells using coronavirus-based vectors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250909

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250909